

Semaglutide Phase-3 Studies Record Fast Recruitment in 2 Months



Lambda achieves enrollment milestone in ongoing Phase-3 Semaglutide studies for Obesity & Type 2 Diabetes Mellitus, in just a span of 2 months:.




SEMAGLUTIDE SUBCUTANEOUS INJECTION

- TWO PHASE-3 STUDIES -

Indications:

Type-2 Diabetes Mellitus
& Obesity



689

PATIENTS SCREENED

514

PATIENTS RANDOMIZED

FAST ENROLLMENT ACROSS

54 SITES,
ACHIEVED WITHIN JUST
2 MONTHS.

	Obesity	Type 2 Diabetes	Total
Screened	336	353	689
Randomized	264	250	514
Active Sites	24	30	54

Connect with our experts to advance your
GLP-1 RA clinical development programs.



BD@lambda-cro.com